Breathlessness Eased In Patients With Rare, Often Fatal Disease
Patients with a rare, deadly disease that mostly affects young women felt a dramatic reduction in breathlessness using an approved drug, according to study results published online in The Journal of Heart and Lung Transplantation. The treatment, continuous intravenous (IV) treprostinil, has already been approved by the U.S. Food and Drug Administration for the treatment of pulmonary arterial hypertension (PAH) based on its similarity to an approved treatment delivered subcutaneously (directly into the skin)…
Original post:
Breathlessness Eased In Patients With Rare, Often Fatal Disease
Related posts:
- Novartis Receives Approval In The European Union For Onbrez® Breezhaler®, A New Once-daily Bronchodilator For Patients With COPD
- Researchers Report Benefits Of New Standard Treatment Study For Rare Pediatric Brain Cancer
- New Medicare Benefit To Provide Chronic Kidney Disease Patients With Education On Treatment Options
- BYETTA Approved For Expanded Use As First-Line Treatment For Type 2 Diabetes
- Shortage Of Lupus Patients Challenges Growing Number Of Clinical Studies